Disparities of Trastuzumab Use in Resource‐Limited or Resource‐Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real‐World Study from China

BACKGROUND. Trastuzumab is a key component of therapy for human epidermal growth receptor 2 (HER2) positive breast cancer. Because real‐world data are lacking, the present research was conducted to evaluate the actual use of and the effectiveness of trastuzumab in the real world in China. METHODS. I...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Li, Jianbin, Wang, Shusen, Wang, Yongsheng, Wang, Xiaojia, Wang, Haibo, Feng, Jifeng, Zhang, Qingyuan, Sun, Tao, Ouyang, Quchang, Yin, Yongmei, Liu, Yinhua, Geng, Cuizhi, Yan, Min, Jiang, Zefei
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2017
Assuntos:
Global Health and Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5679829/
https://ncbi.nlm.nih.gov/pubmed/28798274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0088
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados